1 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
5 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
6 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
7 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
8 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
9 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
10 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
11 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
12 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
13 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
14 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
15 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
16 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
17 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
18 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
19 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
20 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
21 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
22 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
23 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
24 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
25 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
26 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
27 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
28 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
29 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
30 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
31 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
32 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
33 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
34 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
35 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
36 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
37 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
38 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
39 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
40 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
41 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
42 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
43 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
44 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
45 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
46 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
47 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
48 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
49 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
50 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
51 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
52 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
53 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
54 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
55 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
56 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
57 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
58 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
59 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
60 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
61 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
62 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
63 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
64 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
65 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
66 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
67 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
68 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
69 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
70 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
71 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
72 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
73 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
74 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
75 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
76 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
77 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
78 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
79 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
80 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
81 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
82 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
83 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
84 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
85 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
86 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
87 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
88 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
89 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
90 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
91 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
92 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
93 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
94 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
95 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
96 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
97 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
98 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
99 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
100 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
101 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
102 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
103 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
104 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
105 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
106 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
107 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
108 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
109 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
110 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
111 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
112 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
113 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
114 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
115 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
116 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
117 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
118 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
119 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
120 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
121 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
122 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
123 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
124 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
125 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
126 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
127 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
128 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
129 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
130 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
131 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
132 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
133 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
134 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
135 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
136 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
137 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
138 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
139 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
140 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
141 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
142 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
143 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
144 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
145 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
146 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
147 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
148 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
149 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
150 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
151 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
152 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
153 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
154 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
155 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
156 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
157 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
158 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
159 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
160 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
161 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
162 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
163 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
164 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
165 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
166 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
167 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
168 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
169 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
170 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
171 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
172 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
173 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
174 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
175 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
176 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
177 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
178 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
179 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
180 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
181 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
182 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
183 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
184 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
185 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
186 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
187 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
188 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
189 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
190 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
191 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
192 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
193 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
194 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
195 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
196 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
197 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
198 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
199 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
200 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
201 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
202 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
203 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
204 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
205 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
206 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
207 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
208 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
209 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
210 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
211 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
212 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
213 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
214 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
215 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
216 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
217 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
218 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
219 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
220 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
221 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
222 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
223 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
224 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
225 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
226 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
227 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
228 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
229 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
230 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
231 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
232 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
233 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
234 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
235 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
236 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
237 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
238 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
239 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
240 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
241 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
242 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
243 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
244 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
245 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
246 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
247 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
248 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
249 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
250 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
251 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
252 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
253 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
254 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
255 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
256 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
257 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
258 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
259 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
260 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
261 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
262 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
263 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
264 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
265 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
266 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
267 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
268 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
269 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
270 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
271 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
272 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
273 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
274 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
275 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
276 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
277 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
278 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
279 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
280 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
281 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
282 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
283 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
284 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
285 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
286 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
287 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
288 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
289 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
290 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
291 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
292 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
293 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
294 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
295 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
296 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
297 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
298 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
299 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
300 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
301 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
302 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
303 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
304 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
305 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
306 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
307 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
308 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
309 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
310 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
311 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
312 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
313 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
314 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
315 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
316 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
317 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
318 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
319 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
320 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
321 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
322 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
323 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
324 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
325 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
326 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
327 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
328 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
329 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
330 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
331 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
332 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
333 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
334 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
335 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
336 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
337 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
338 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
339 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
340 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
341 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
342 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
343 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
344 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
345 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
346 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
347 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
348 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
349 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
350 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
351 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
352 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
353 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
354 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
355 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
356 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
357 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
358 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
359 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
360 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
361 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
362 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
363 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
364 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
365 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
366 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
367 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
368 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
369 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
370 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
371 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
372 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
373 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
374 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
375 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
376 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
377 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
378 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
379 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
380 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
381 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
382 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
383 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
384 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
385 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
386 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
387 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
388 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
389 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
390 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
391 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
392 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
393 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
394 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
395 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
396 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
397 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
398 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
399 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
400 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
401 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
402 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
403 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
404 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
405 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
406 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
407 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
408 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
409 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
410 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
411 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
412 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
413 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
414 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
415 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
416 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
417 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
418 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
419 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
420 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
421 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
422 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
423 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
424 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
425 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
426 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
427 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
428 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
429 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
430 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
431 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
432 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
433 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
434 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
435 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
436 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
437 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
438 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
439 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
440 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
441 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
442 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
443 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
444 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
445 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
446 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
447 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
448 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
449 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
450 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
451 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
452 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
453 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
454 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
455 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
456 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
457 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
458 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
459 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
460 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
461 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
462 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
463 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
464 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
465 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
466 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
467 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
468 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
469 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
470 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
471 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
472 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
473 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
474 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
475 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
476 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
477 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
478 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
479 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
480 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
481 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
482 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
483 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
484 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
485 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
486 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
487 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
488 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
489 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
490 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
491 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
492 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
493 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
494 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
495 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
496 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
497 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
498 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
499 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
500 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
501 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
502 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
503 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
504 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
505 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
506 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
507 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
508 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
509 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
510 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
511 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
512 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
513 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
514 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
515 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
516 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
517 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
518 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
519 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
520 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
521 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
522 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
523 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
524 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
525 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
526 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
527 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
528 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
529 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
530 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
531 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
532 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
533 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
534 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
535 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
536 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
537 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
538 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
539 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
540 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
541 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
542 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
543 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
544 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
545 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
546 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
547 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
548 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
549 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
550 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
551 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
552 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
553 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
554 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
555 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
556 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
557 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
558 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
559 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
560 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
561 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
562 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
563 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
564 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
565 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
566 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
567 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
568 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
569 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
570 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
571 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
572 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
573 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
574 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
575 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
576 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
577 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
578 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
579 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
580 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
581 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
582 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
583 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
584 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
585 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
586 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
587 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
588 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
589 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
590 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
591 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
592 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
593 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
594 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
595 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
596 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
597 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
598 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
599 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
600 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
601 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
602 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
603 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
604 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
605 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
606 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
607 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
608 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
609 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
610 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
611 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
612 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
613 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
614 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
615 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
616 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
617 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
618 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
619 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
620 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
621 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
622 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
623 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
624 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
625 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
626 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
627 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
628 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
629 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
630 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
631 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
632 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
633 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
634 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
635 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
636 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
637 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
638 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
639 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
640 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
641 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
642 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
643 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
644 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
645 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
646 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
647 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
648 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
649 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
650 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
651 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
652 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
653 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
654 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
655 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
656 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
657 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
658 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
659 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
660 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
661 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
662 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
663 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
664 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
665 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
666 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
667 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
668 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
669 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
670 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
671 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
672 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
673 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
674 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
675 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
676 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
677 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
678 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
679 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
680 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
681 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
682 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
683 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
684 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
685 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
686 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
687 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
688 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
689 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
690 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
691 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
692 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
693 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
694 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
695 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
696 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
697 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
698 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
699 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
700 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
701 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
702 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
703 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
704 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
705 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
706 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
707 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
708 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
709 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
710 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
711 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
712 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
713 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
714 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
715 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
716 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
717 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
718 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
719 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
720 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
721 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
722 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
723 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
724 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
725 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
726 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
727 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
728 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
729 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
730 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
731 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
732 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
733 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
734 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
735 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
736 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
737 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
738 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
739 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
740 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
741 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
742 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
743 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
744 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
745 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
746 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
747 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
748 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
749 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
750 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
751 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
752 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
753 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
754 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
755 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
756 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
757 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
758 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
759 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
760 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
761 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
762 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
763 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
764 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
765 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
766 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
767 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
768 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
769 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
770 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
771 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
772 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
773 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
774 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
775 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
776 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
777 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
778 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
779 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
780 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
781 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
782 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
783 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
784 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
785 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
786 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
787 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
788 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
789 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
790 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
791 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
792 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
793 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
794 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
795 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
796 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
797 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
798 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
799 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
800 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
801 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
802 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
803 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
804 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
805 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
806 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
807 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
808 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
809 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
810 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
811 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
812 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
813 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
814 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
815 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
816 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
817 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
818 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
819 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
820 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
821 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
822 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
823 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
824 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
825 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
826 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
827 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
828 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
829 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
830 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
831 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
832 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
833 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
834 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
835 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
836 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
837 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
838 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
839 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
840 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
841 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
842 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
843 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
844 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
845 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
846 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
847 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
848 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
849 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
850 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
851 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
852 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
853 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
854 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
855 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
856 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
857 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
858 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
859 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
860 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
861 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
862 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
863 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
864 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
865 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
866 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
867 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
868 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
869 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
870 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
871 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
872 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
873 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
874 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
875 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
876 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
877 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
878 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
879 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
880 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
881 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
882 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
883 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
884 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
885 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
886 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
887 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
888 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
889 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
890 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
891 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
892 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
893 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
894 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
895 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
896 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
897 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
898 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
899 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
900 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
901 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
902 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
903 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
904 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
905 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
906 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
907 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
908 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
909 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
910 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
911 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
912 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
913 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
914 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
915 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
916 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
917 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
918 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
919 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
920 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
921 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
922 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
923 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
924 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
925 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
926 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
927 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
928 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
929 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
930 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
931 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
932 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
933 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
934 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
935 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
936 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
937 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
938 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
939 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
940 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
941 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
942 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
943 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
944 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
945 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
946 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
947 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
948 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
949 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
950 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
951 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
952 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
953 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
954 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
955 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
956 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
957 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
958 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
959 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
960 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
961 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
962 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
963 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
964 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
965 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
966 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
967 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
968 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
969 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
970 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
971 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
972 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
973 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
974 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
975 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
976 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
977 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
978 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
979 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
980 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
981 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
982 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
983 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
984 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
985 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
986 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
987 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
988 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
989 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
990 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
991 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
992 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
993 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
994 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
995 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
996 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
997 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
998 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
999 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1000 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1001 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1002 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1003 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1004 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1005 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1006 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1007 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1008 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1009 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1010 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1011 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1012 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1013 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1014 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1015 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1016 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1017 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1018 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1019 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1020 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1021 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1022 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1023 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1024 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1025 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1026 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1027 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1028 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1029 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1030 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1031 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1032 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1033 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1034 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1035 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1036 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1037 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1038 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1039 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1040 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1041 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1042 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1043 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1044 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1045 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1046 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1047 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1048 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1049 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1050 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1051 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1052 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1053 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1054 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1055 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1056 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1057 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1058 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1059 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1060 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1061 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1062 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1063 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1064 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1065 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1066 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1067 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1068 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1069 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1070 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1071 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1072 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1073 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1074 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1075 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1076 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1077 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1078 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1079 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1080 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1081 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1082 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1083 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1084 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1085 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1086 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1087 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1088 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1089 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1090 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1091 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1092 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1093 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1094 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1095 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1096 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1097 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1098 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1099 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1100 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1101 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1102 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1103 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1104 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1105 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1106 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1107 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1108 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1109 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1110 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1111 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1112 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1113 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1114 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1115 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1116 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1117 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1118 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1119 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1120 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1121 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1122 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1123 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1124 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1125 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1126 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1127 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1128 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1129 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1130 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1131 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1132 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1133 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1134 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1135 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1136 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1137 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1138 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1139 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1140 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1141 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1142 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1143 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1144 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1145 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1146 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1147 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1148 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1149 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1150 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1151 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1152 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1153 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1154 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1155 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1156 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1157 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1158 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1159 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1160 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1161 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1162 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1163 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1164 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1165 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1166 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1167 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1168 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1169 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1170 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1171 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1172 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1173 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1174 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1175 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1176 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1177 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1178 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1179 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1180 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1181 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1182 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1183 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1184 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1185 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1186 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1187 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1188 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1189 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1190 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1191 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1192 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1193 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1194 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1195 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1196 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1197 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1198 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1199 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1200 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1201 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1202 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1203 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1204 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1205 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1206 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1207 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1208 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1209 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1210 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1211 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1212 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1213 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1214 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1215 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1216 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1217 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1218 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1219 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1220 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1221 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1222 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1223 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1224 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1225 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1226 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1227 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1228 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1229 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1230 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1231 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1232 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1233 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1234 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1235 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1236 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1237 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1238 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1239 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1240 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1241 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1242 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1243 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1244 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1245 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1246 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1247 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1248 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1249 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1250 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1251 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1252 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1253 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1254 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1255 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1256 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1257 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1258 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1259 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1260 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1261 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1262 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1263 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1264 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1265 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1266 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1267 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1268 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1269 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1270 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1271 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1272 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1273 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1274 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1275 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1276 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1277 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1278 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1279 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1280 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1281 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1282 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1283 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1284 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1285 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1286 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1287 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1288 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1289 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1290 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1291 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1292 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1293 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1294 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1295 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1296 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1297 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1298 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1299 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1300 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1301 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1302 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1303 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1304 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1305 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1306 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1307 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1308 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1309 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1310 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1311 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1312 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1313 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1314 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1315 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1316 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1317 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1318 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1319 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1320 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1321 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1322 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1323 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1324 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1325 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1326 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1327 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1328 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1329 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1330 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1331 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1332 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1333 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1334 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1335 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1336 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1337 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1338 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1339 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1340 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1341 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1342 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1343 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1344 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1345 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1346 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1347 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1348 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1349 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1350 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1351 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1352 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1353 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1354 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1355 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1356 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1357 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1358 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1359 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1360 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1361 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1362 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1363 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1364 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1365 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1366 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1367 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1368 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1369 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1370 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1371 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1372 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1373 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1374 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1375 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1376 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1377 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1378 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1379 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1380 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1381 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1382 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1383 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1384 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1385 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1386 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1387 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1388 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1389 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1390 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1391 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1392 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1393 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1394 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1395 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1396 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1397 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1398 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1399 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1400 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1401 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1402 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1403 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1404 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1405 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1406 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1407 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1408 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1409 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1410 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1411 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1412 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1413 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1414 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1415 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1416 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1417 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1418 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1419 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1420 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1421 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1422 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1423 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1424 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1425 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1426 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1427 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1428 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1429 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1430 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1431 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1432 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1433 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1434 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1435 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1436 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1437 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1438 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1439 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1440 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1441 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1442 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1443 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1444 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1445 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1446 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1447 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1448 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1449 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1450 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1451 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1452 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1453 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1454 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1455 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1456 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1457 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1458 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1459 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1460 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1461 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1462 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1463 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1464 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1465 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1466 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1467 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1468 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1469 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1470 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1471 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1472 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1473 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1474 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1475 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1476 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1477 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1478 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1479 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1480 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1481 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1482 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1483 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1484 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1485 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1486 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1487 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1488 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1489 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1490 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1491 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1492 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1493 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1494 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1495 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1496 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1497 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1498 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1499 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1500 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1501 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1502 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1503 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1504 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1505 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1506 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1507 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1508 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1509 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1510 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1511 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1512 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1513 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1514 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1515 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1516 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1517 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1518 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1519 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1520 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1521 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1522 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1523 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1524 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1525 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1526 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1527 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1528 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1529 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1530 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1531 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1532 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1533 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1534 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1535 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1536 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1537 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1538 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1539 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1540 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1541 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1542 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1543 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1544 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1545 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1546 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1547 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1548 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1549 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1550 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1551 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1552 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1553 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1554 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1555 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1556 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1557 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1558 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1559 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1560 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1561 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1562 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1563 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1564 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1565 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1566 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1567 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1568 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1569 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1570 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1571 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1572 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1573 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1574 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1575 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1576 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1577 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1578 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1579 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1580 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1581 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1582 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1583 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1584 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1585 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1586 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1587 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1588 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1589 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1590 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1591 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1592 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1593 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1594 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1595 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1596 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1597 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1598 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1599 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1600 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1601 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1602 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1603 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1604 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1605 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1606 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1607 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1608 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1609 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1610 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1611 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1612 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1613 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1614 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1615 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1616 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1617 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1618 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1619 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1620 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1621 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1622 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1623 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1624 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1625 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1626 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1627 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1628 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1629 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1630 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1631 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1632 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1633 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1634 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1635 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1636 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1637 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1638 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1639 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1640 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1641 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1642 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1643 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1644 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1645 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1646 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1647 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1648 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1649 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1650 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1651 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1652 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1653 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1654 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1655 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1656 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1657 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1658 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1659 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1660 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1661 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1662 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1663 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1664 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1665 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1666 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1667 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1668 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1669 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1670 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1671 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1672 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1673 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1674 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1675 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1676 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1677 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1678 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1679 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1680 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1681 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1682 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1683 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1684 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1685 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1686 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1687 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1688 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1689 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1690 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1691 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1692 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1693 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1694 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1695 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1696 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1697 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1698 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1699 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1700 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1701 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1702 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1703 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1704 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1705 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1706 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1707 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1708 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1709 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1710 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1711 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1712 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1713 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1714 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1715 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1716 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1717 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1718 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1719 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1720 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1721 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1722 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1723 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1724 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1725 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1726 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1727 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1728 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1729 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1730 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1731 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1732 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1733 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1734 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1735 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1736 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1737 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1738 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1739 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1740 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1741 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1742 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1743 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1744 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1745 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1746 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1747 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1748 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1749 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1750 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1751 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1752 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1753 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1754 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1755 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1756 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1757 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1758 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1759 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1760 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1761 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1762 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1763 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1764 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1765 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1766 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1767 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1768 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1769 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1770 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1771 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1772 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1773 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1774 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1775 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1776 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1777 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1778 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1779 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1780 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1781 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1782 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1783 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1784 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1785 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1786 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1787 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1788 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1789 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1790 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1791 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1792 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1793 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1794 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1795 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1796 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1797 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1798 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1799 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1800 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1801 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1802 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1803 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1804 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1805 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1806 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1807 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1808 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1809 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1810 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1811 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1812 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1813 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1814 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1815 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1816 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1817 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1818 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1819 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1820 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1821 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1822 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1823 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1824 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1825 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1826 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1827 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1828 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1829 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1830 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1831 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1832 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1833 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1834 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1835 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1836 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1837 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1838 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1839 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1840 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1841 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1842 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1843 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1844 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1845 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1846 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1847 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1848 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1849 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1850 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1851 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1852 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1853 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1854 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1855 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1856 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1857 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1858 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1859 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1860 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1861 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1862 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1863 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1864 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1865 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1866 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1867 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1868 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1869 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1870 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1871 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1872 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1873 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1874 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1875 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1876 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1877 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1878 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1879 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1880 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1881 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1882 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1883 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1884 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1885 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1886 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1887 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1888 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1889 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1890 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1891 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1892 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1893 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1894 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1895 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1896 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1897 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1898 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1899 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1900 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1901 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1902 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1903 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1904 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1905 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1906 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1907 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1908 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1909 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1910 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1911 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1912 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1913 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1914 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1915 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1916 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1917 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1918 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1919 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1920 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1921 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1922 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1923 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1924 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1925 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1926 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1927 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1928 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1929 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1930 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1931 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1932 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1933 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1934 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1935 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1936 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1937 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1938 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1939 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1940 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1941 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1942 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1943 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1944 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1945 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1946 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1947 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1948 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1949 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1950 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1951 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1952 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1953 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1954 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1955 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1956 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1957 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1958 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1959 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1960 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1961 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1962 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1963 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1964 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1965 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1966 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1967 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1968 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1969 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1970 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1971 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1972 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1973 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1974 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1975 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1976 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1977 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1978 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1979 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1980 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1981 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1982 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1983 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1984 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1985 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1986 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1987 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1988 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1989 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1990 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1991 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1992 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1993 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1994 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1995 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1996 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1997 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1998 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
1999 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2000 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2001 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2002 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2003 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2004 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2005 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2006 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2007 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2008 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2009 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2010 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2011 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2012 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2013 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2014 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2015 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2016 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2017 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2018 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2019 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2020 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2021 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2022 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2023 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2024 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2025 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2026 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2027 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2028 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2029 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2030 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2031 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2032 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2033 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2034 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2035 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2036 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2037 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2038 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2039 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2040 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2041 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2042 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2043 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2044 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2045 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2046 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2047 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2048 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2049 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2050 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2051 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2052 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2053 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2054 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2055 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2056 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2057 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2058 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2059 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2060 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2061 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2062 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2063 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2064 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2065 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2066 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2067 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2068 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2069 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2070 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2071 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2072 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2073 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2074 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2075 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2076 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2077 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2078 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2079 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2080 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2081 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2082 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2083 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2084 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2085 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2086 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2087 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2088 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2089 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2090 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2091 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2092 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2093 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2094 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2095 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2096 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2097 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2098 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2099 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2100 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2101 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2102 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2103 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2104 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2105 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2106 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2107 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2108 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2109 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2110 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2111 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2112 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2113 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2114 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2115 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2116 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2117 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2118 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2119 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2120 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2121 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2122 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2123 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2124 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2125 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2126 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2127 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2128 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2129 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2130 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2131 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2132 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2133 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2134 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2135 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2136 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2137 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2138 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2139 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2140 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2141 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2142 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2143 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2144 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2145 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2146 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2147 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2148 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2149 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2150 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2151 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2152 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2153 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2154 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2155 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2156 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2157 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2158 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2159 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2160 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2161 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2162 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2163 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2164 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2165 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2166 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2167 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2168 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2169 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2170 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2171 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2172 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2173 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2174 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2175 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2176 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2177 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2178 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2179 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2180 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2181 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2182 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2183 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2184 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2185 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2186 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2187 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2188 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2189 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2190 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2191 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2192 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2193 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2194 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2195 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2196 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2197 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2198 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2199 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2200 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2201 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2202 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2203 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2204 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2205 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2206 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2207 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2208 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2209 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2210 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2211 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2212 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2213 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2214 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2215 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2216 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2217 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2218 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2219 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2220 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2221 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2222 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2223 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2224 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2225 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2226 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2227 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2228 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2229 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2230 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2231 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2232 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2233 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2234 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2235 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2236 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2237 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2238 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2239 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2240 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2241 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2242 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2243 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2244 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2245 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2246 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2247 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2248 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2249 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2250 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2251 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2252 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2253 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2254 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2255 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2256 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2257 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2258 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2259 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2260 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2261 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2262 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2263 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2264 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2265 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2266 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2267 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2268 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2269 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2270 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2271 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2272 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2273 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2274 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2275 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2276 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2277 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2278 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2279 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2280 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2281 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2282 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2283 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2284 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2285 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2286 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2287 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2288 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2289 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2290 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2291 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2292 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2293 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2294 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2295 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2296 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2297 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2298 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2299 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2300 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2301 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2302 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2303 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2304 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2305 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2306 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2307 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2308 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2309 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2310 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2311 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2312 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2313 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2314 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2315 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2316 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2317 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2318 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2319 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2320 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2321 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2322 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2323 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2324 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2325 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2326 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2327 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2328 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2329 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2330 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2331 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2332 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2333 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2334 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2335 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2336 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2337 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2338 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2339 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2340 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2341 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2342 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2343 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2344 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2345 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2346 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2347 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2348 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2349 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2350 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2351 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2352 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2353 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2354 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2355 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2356 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2357 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2358 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2359 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2360 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2361 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2362 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2363 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2364 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2365 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2366 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2367 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2368 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2369 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2370 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2371 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2372 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2373 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2374 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2375 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2376 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2377 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2378 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2379 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2380 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2381 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2382 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2383 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2384 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2385 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2386 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2387 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2388 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2389 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2390 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2391 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2392 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2393 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2394 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2395 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2396 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2397 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2398 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2399 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2400 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2401 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2402 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2403 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2404 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2405 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2406 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2407 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2408 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2409 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2410 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2411 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2412 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2413 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2414 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2415 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2416 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2417 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2418 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2419 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2420 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2421 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2422 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2423 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2424 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2425 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2426 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2427 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2428 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2429 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2430 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2431 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2432 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2433 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2434 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2435 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2436 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2437 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2438 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2439 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2440 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2441 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2442 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2443 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2444 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2445 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2446 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2447 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2448 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2449 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2450 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2451 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2452 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2453 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2454 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2455 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2456 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2457 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2458 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2459 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2460 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2461 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2462 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2463 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2464 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2465 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2466 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2467 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2468 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2469 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2470 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2471 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2472 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2473 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2474 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2475 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2476 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2477 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2478 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2479 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2480 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2481 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2482 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2483 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2484 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2485 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2486 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2487 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2488 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2489 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2490 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2491 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2492 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2493 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2494 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2495 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2496 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2497 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2498 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2499 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2500 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2501 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2502 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2503 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2504 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2505 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2506 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2507 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2508 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2509 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2510 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2511 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2512 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2513 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2514 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2515 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2516 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2517 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2518 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2519 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2520 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2521 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2522 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2523 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2524 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2525 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2526 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2527 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2528 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2529 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2530 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2531 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2532 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2533 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2534 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2535 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2536 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2537 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2538 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2539 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2540 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2541 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2542 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2543 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2544 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2545 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2546 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2547 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2548 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2549 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2550 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2551 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2552 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2553 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2554 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2555 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2556 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2557 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2558 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2559 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2560 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2561 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2562 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2563 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2564 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2565 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2566 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2567 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2568 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2569 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2570 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2571 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2572 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2573 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2574 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2575 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2576 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2577 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2578 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2579 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2580 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2581 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2582 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2583 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2584 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2585 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2586 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2587 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2588 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2589 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2590 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2591 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2592 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2593 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2594 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2595 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2596 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2597 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2598 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2599 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2600 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2601 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2602 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2603 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2604 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2605 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2606 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2607 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2608 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2609 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2610 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2611 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2612 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2613 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2614 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2615 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2616 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2617 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2618 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2619 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2620 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2621 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2622 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2623 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2624 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2625 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2626 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2627 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2628 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2629 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2630 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2631 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2632 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2633 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2634 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2635 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2636 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2637 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2638 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2639 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2640 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2641 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2642 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2643 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2644 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2645 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2646 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2647 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2648 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2649 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2650 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2651 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2652 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2653 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2654 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2655 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2656 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2657 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2658 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2659 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2660 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2661 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2662 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2663 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2664 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2665 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2666 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2667 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2668 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2669 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2670 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2671 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2672 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2673 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2674 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2675 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2676 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2677 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2678 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2679 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2680 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2681 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2682 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2683 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2684 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2685 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2686 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2687 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2688 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2689 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2690 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2691 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2692 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2693 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2694 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2695 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2696 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2697 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2698 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2699 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2700 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2701 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2702 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2703 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2704 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2705 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2706 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2707 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2708 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2709 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2710 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2711 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2712 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2713 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2714 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2715 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2716 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2717 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2718 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2719 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2720 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2721 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2722 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2723 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2724 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2725 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2726 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2727 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2728 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2729 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2730 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2731 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2732 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2733 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2734 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2735 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2736 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2737 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2738 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2739 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2740 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2741 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2742 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2743 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2744 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2745 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2746 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2747 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2748 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2749 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2750 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2751 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2752 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2753 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2754 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2755 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2756 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2757 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2758 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2759 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2760 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2761 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2762 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2763 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2764 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2765 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2766 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2767 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2768 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2769 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2770 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2771 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2772 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2773 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2774 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2775 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2776 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2777 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2778 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2779 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2780 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2781 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2782 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2783 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2784 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2785 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2786 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2787 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2788 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2789 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2790 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2791 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2792 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2793 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2794 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2795 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2796 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2797 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2798 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2799 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2800 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2801 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2802 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2803 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2804 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2805 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2806 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2807 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2808 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2809 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2810 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2811 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2812 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2813 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2814 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2815 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2816 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2817 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2818 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2819 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2820 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2821 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2822 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2823 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2824 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2825 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2826 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2827 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2828 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2829 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2830 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2831 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2832 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2833 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2834 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2835 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2836 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2837 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2838 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2839 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2840 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2841 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2842 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2843 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2844 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2845 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2846 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2847 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2848 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2849 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2850 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2851 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2852 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2853 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2854 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2855 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2856 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2857 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2858 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2859 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2860 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2861 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2862 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2863 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2864 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2865 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2866 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2867 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2868 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2869 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2870 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2871 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2872 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2873 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2874 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2875 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2876 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2877 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2878 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2879 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2880 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2881 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2882 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2883 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2884 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2885 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2886 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2887 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2888 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2889 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2890 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2891 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2892 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2893 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2894 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2895 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2896 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2897 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2898 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2899 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2900 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2901 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2902 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2903 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2904 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2905 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2906 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2907 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2908 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2909 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2910 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2911 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2912 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2913 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2914 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2915 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2916 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2917 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2918 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2919 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2920 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2921 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2922 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2923 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2924 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2925 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2926 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2927 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2928 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2929 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2930 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2931 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2932 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2933 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2934 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2935 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2936 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2937 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2938 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2939 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2940 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2941 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2942 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2943 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2944 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2945 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2946 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2947 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2948 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2949 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2950 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2951 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2952 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2953 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2954 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2955 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2956 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2957 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2958 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2959 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2960 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2961 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2962 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2963 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2964 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2965 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2966 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2967 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2968 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2969 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2970 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2971 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2972 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2973 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2974 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2975 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2976 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2977 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2978 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2979 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2980 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2981 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2982 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2983 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2984 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2985 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2986 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2987 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2988 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2989 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2990 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2991 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2992 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2993 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2994 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2995 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2996 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2997 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2998 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
2999 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3000 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3001 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3002 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3003 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3004 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3005 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3006 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3007 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3008 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3009 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3010 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3011 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3012 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3013 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3014 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3015 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3016 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3017 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3018 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3019 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3020 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3021 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3022 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3023 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3024 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3025 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3026 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3027 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3028 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3029 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3030 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3031 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3032 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3033 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3034 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3035 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3036 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3037 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3038 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3039 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3040 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3041 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3042 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3043 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3044 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3045 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3046 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3047 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3048 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3049 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3050 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3051 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3052 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3053 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3054 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3055 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3056 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3057 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3058 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3059 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3060 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3061 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3062 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3063 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3064 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3065 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3066 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3067 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3068 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3069 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3070 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3071 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3072 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3073 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3074 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3075 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3076 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3077 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3078 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3079 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3080 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3081 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3082 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3083 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3084 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3085 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3086 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3087 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3088 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3089 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3090 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3091 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3092 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3093 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3094 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3095 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3096 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3097 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3098 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3099 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3100 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3101 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3102 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3103 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3104 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3105 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3106 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3107 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3108 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3109 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3110 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3111 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3112 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3113 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3114 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3115 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3116 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3117 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3118 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3119 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3120 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3121 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3122 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3123 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3124 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3125 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3126 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3127 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3128 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3129 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3130 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3131 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3132 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3133 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3134 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3135 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3136 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3137 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3138 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3139 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3140 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3141 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3142 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3143 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3144 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3145 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3146 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3147 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3148 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3149 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3150 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3151 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3152 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3153 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3154 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3155 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3156 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3157 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3158 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3159 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3160 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3161 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3162 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3163 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3164 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3165 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3166 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3167 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3168 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3169 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3170 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3171 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3172 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3173 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3174 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3175 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3176 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3177 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3178 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3179 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3180 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3181 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3182 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3183 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3184 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3185 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3186 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3187 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3188 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3189 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3190 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3191 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3192 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3193 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3194 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3195 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3196 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3197 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3198 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3199 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3200 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3201 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3202 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3203 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3204 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3205 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3206 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3207 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3208 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3209 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3210 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3211 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3212 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3213 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3214 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3215 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3216 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3217 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3218 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3219 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3220 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3221 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3222 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3223 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3224 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3225 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3226 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3227 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3228 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3229 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3230 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3231 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3232 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3233 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3234 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3235 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3236 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3237 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3238 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3239 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3240 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3241 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3242 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3243 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3244 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3245 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3246 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3247 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3248 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3249 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3250 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3251 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3252 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3253 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3254 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3255 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3256 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3257 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3258 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3259 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3260 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3261 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3262 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3263 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3264 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3265 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3266 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3267 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3268 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3269 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3270 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3271 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3272 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3273 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3274 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3275 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3276 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3277 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3278 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3279 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3280 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3281 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3282 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3283 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3284 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3285 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3286 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3287 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3288 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3289 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3290 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3291 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3292 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3293 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3294 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3295 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3296 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3297 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3298 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3299 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3300 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3301 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3302 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3303 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3304 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3305 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3306 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3307 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3308 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3309 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3310 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3311 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3312 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3313 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3314 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3315 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3316 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3317 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3318 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3319 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3320 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3321 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3322 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3323 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3324 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3325 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3326 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3327 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3328 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3329 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3330 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3331 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3332 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3333 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3334 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3335 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3336 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3337 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3338 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3339 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3340 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3341 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3342 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3343 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3344 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3345 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3346 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3347 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3348 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3349 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3350 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3351 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3352 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3353 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3354 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3355 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3356 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3357 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3358 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3359 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3360 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3361 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3362 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3363 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3364 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3365 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3366 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3367 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3368 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3369 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3370 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3371 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3372 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3373 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3374 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3375 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3376 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3377 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3378 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3379 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3380 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3381 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3382 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3383 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3384 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3385 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3386 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3387 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3388 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3389 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3390 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3391 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3392 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3393 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3394 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3395 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3396 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3397 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3398 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3399 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3400 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3401 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3402 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3403 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3404 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3405 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3406 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3407 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3408 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3409 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3410 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3411 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3412 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3413 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3414 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3415 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3416 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3417 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3418 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3419 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3420 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3421 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3422 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3423 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3424 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3425 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3426 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3427 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3428 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3429 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3430 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3431 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3432 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3433 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3434 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3435 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3436 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3437 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3438 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3439 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3440 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3441 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3442 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3443 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3444 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3445 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3446 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3447 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3448 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3449 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3450 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3451 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3452 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3453 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3454 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3455 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3456 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3457 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3458 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3459 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3460 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3461 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3462 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3463 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3464 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3465 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3466 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3467 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3468 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3469 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3470 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3471 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3472 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3473 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3474 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3475 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3476 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3477 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3478 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3479 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3480 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3481 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3482 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3483 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3484 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3485 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3486 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3487 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3488 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3489 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3490 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3491 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3492 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3493 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3494 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3495 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3496 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3497 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3498 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3499 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3500 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3501 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3502 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3503 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3504 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3505 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3506 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3507 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3508 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3509 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3510 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3511 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3512 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3513 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3514 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3515 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3516 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3517 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3518 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3519 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3520 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3521 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3522 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3523 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3524 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3525 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3526 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3527 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3528 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3529 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3530 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3531 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3532 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3533 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3534 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3535 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3536 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3537 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3538 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3539 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3540 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3541 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3542 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3543 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3544 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3545 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3546 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3547 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3548 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3549 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3550 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3551 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3552 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3553 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3554 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3555 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3556 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3557 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3558 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3559 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3560 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3561 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3562 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3563 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3564 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3565 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3566 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3567 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3568 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3569 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3570 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3571 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3572 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3573 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3574 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3575 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3576 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3577 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3578 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3579 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3580 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3581 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3582 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3583 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3584 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3585 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3586 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3587 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3588 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3589 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3590 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3591 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3592 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3593 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3594 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3595 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3596 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3597 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3598 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3599 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3600 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3601 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3602 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3603 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3604 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3605 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3606 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3607 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3608 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3609 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3610 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3611 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3612 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3613 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3614 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3615 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3616 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3617 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3618 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3619 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3620 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3621 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3622 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3623 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3624 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3625 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3626 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3627 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3628 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3629 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3630 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3631 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3632 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3633 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3634 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3635 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3636 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3637 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3638 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3639 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3640 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3641 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3642 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3643 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3644 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3645 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3646 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3647 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3648 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3649 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3650 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3651 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3652 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3653 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3654 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3655 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3656 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3657 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3658 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3659 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3660 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3661 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3662 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3663 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3664 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3665 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3666 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3667 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3668 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3669 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3670 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3671 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3672 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3673 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3674 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3675 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3676 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3677 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3678 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3679 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3680 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3681 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3682 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3683 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3684 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3685 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3686 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3687 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3688 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3689 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3690 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3691 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3692 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3693 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3694 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3695 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3696 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3697 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3698 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3699 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3700 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3701 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3702 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3703 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3704 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3705 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3706 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3707 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3708 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3709 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3710 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3711 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3712 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3713 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3714 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3715 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3716 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3717 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3718 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3719 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3720 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3721 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3722 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3723 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3724 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3725 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3726 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3727 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3728 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3729 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3730 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3731 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3732 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3733 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3734 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3735 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3736 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3737 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3738 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3739 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3740 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3741 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3742 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3743 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3744 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3745 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3746 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3747 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3748 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3749 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3750 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3751 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3752 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3753 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3754 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3755 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3756 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3757 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3758 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3759 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3760 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3761 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3762 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3763 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3764 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3765 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3766 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3767 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3768 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3769 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3770 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3771 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3772 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3773 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3774 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3775 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3776 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3777 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3778 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3779 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3780 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3781 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3782 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3783 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3784 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3785 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3786 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3787 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3788 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3789 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3790 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3791 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3792 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3793 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3794 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3795 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3796 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3797 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3798 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3799 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3800 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3801 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3802 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3803 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3804 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3805 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3806 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3807 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3808 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3809 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3810 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3811 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3812 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3813 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3814 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3815 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3816 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3817 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3818 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3819 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3820 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3821 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3822 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3823 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3824 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3825 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3826 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3827 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3828 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3829 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3830 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3831 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3832 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3833 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3834 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3835 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3836 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3837 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3838 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3839 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3840 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3841 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3842 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3843 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3844 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3845 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3846 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3847 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3848 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3849 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3850 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3851 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3852 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3853 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3854 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3855 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3856 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3857 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3858 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3859 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3860 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3861 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3862 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3863 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3864 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3865 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3866 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3867 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3868 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3869 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3870 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3871 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3872 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3873 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3874 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3875 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3876 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3877 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3878 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3879 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3880 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3881 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3882 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3883 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3884 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3885 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3886 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3887 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3888 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3889 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3890 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3891 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3892 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3893 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3894 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3895 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3896 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3897 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3898 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3899 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3900 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3901 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3902 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3903 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3904 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3905 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3906 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3907 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3908 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3909 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3910 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3911 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3912 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3913 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3914 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3915 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3916 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3917 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3918 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3919 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3920 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3921 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3922 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3923 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3924 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3925 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3926 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3927 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3928 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3929 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3930 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3931 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3932 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3933 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3934 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3935 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3936 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3937 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3938 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3939 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3940 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3941 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3942 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3943 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3944 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3945 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3946 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3947 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3948 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3949 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3950 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3951 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3952 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3953 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3954 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3955 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3956 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3957 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3958 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3959 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3960 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3961 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3962 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3963 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3964 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3965 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3966 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3967 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3968 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3969 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3970 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3971 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3972 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3973 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3974 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3975 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3976 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3977 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3978 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3979 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3980 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3981 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3982 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3983 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3984 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3985 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3986 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3987 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3988 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3989 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3990 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3991 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3992 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3993 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3994 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3995 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3996 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3997 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3998 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
3999 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4000 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4001 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4002 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4003 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4004 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4005 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4006 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4007 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4008 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4009 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4010 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4011 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4012 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4013 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4014 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4015 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4016 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4017 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4018 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4019 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4020 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4021 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4022 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4023 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4024 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4025 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4026 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4027 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4028 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4029 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4030 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4031 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4032 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4033 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4034 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4035 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4036 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4037 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4038 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4039 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4040 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4041 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4042 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4043 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4044 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4045 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4046 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4047 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4048 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4049 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4050 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4051 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4052 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4053 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4054 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4055 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4056 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4057 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4058 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4059 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4060 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4061 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4062 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4063 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4064 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4065 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4066 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4067 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4068 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4069 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4070 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4071 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4072 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4073 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4074 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4075 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4076 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4077 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4078 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4079 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4080 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4081 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4082 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4083 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4084 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4085 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4086 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4087 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4088 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4089 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4090 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4091 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4092 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4093 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4094 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4095 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
4096 JHM IRB review of research involving unlicensed or unapproved drugs, botanicals, biologicals, or other substances (e.g., food additives, food derivatives, vitamins, minerals, extracts, etc.) must be conducted at a convened meeting. The review must include the presence of a P&T IRB member who will make a recommendation concerning the risks and proposed benefits of each product to be used in the study. The IRB review will address the need for submission of an FDA Investigational New Drug Application (IND) prior to the use of the test article in the research study. The IRB may determine that an IND is not required if all the conditions set forth in 21 CFR 312.2(b) have been met. The IRB will determine whether to require submission of an IND, or if appropriate, to require the Primary Investigator (PI) to seek clarification from the FDA about the need for obtaining an IND before the IRB completes its review. 
